Scholarlink

Aims <p><i>P. gingivalis</i> is a significant pathogen in periodontal disease, a chronic inflammatory condition disturbing tooth-supporting tissue. Its systemic distribution has been linked to cardiovascular disease, rheumatoid arthritis, and Alzheimer’s disease. This study aimed to design and evaluate a novel antimicrobial peptide targeting <i>P. gingivalis</i>.</p> Methods <p>The active site of bacteriocin nisin was first identified through bioinformatics analysis and subsequently enhanced structurally by adding arginine at the N-terminus. The antimicrobial properties, stability and toxicity of the modified peptide were investigated using in silico tools (AMPA, AMP Scanner, sAMPpred-GAT). In vitro assays measured its effects on <i>P. gingivalis</i> growth (OD600), viability (CFU/mL) and biofilm formation at concentrations from 4–128&#xa0;µg/mL.</p> Findings <p>Computational analysis indicated the antimicrobial potency, structural resilience, and mammalian cell safety of this peptide. In vitro evaluation showed dose-dependent inhibition of <i>P. gingivalis</i> growth (MIC: 32&#xa0;µg/mL), bactericidal activity (MBC: 128&#xa0;µg/mL), and meaningful biofilm reduction (64&#xa0;µg/mL).</p> Conclusion <p>The engineered peptide holds promising efficacy against <i>P. gingivalis</i>, supporting AMPs as potential therapeutics for periodontal and systemic <i>P. gingivalis</i>-associated conditions. Further mechanistic and preclinical studies are warranted.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Assessment of the Antimicrobial Efficacy of a Novel Peptide Against Porphyromonas gingivalis: An in Silico and in Vitro Investigation

  • 期刊论文

  • 发表日期：

    2025年8月22日

查看全文
  • Maryam Kiani Golshoui,
  • Saeed Hemmatzadeh,
  • Mohammad Sadegh Ghalyanchi Langeroudi,
  • Kaveh Bazyar,
  • Parisa Bonyadi,
  • Ali Shivaee,
  • Kumarss Amini,
  • Behrooz Sadeghi Kalani

摘要

Aims

P. gingivalis is a significant pathogen in periodontal disease, a chronic inflammatory condition disturbing tooth-supporting tissue. Its systemic distribution has been linked to cardiovascular disease, rheumatoid arthritis, and Alzheimer’s disease. This study aimed to design and evaluate a novel antimicrobial peptide targeting P. gingivalis.

Methods

The active site of bacteriocin nisin was first identified through bioinformatics analysis and subsequently enhanced structurally by adding arginine at the N-terminus. The antimicrobial properties, stability and toxicity of the modified peptide were investigated using in silico tools (AMPA, AMP Scanner, sAMPpred-GAT). In vitro assays measured its effects on P. gingivalis growth (OD600), viability (CFU/mL) and biofilm formation at concentrations from 4–128 µg/mL.

Findings

Computational analysis indicated the antimicrobial potency, structural resilience, and mammalian cell safety of this peptide. In vitro evaluation showed dose-dependent inhibition of P. gingivalis growth (MIC: 32 µg/mL), bactericidal activity (MBC: 128 µg/mL), and meaningful biofilm reduction (64 µg/mL).

Conclusion

The engineered peptide holds promising efficacy against P. gingivalis, supporting AMPs as potential therapeutics for periodontal and systemic P. gingivalis-associated conditions. Further mechanistic and preclinical studies are warranted.